1Decaux G.Difference is solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985[].Journal of Laboratory and Clinical Medicine.2001
2Gadano A,Moreau R,Pessione F,et al.Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis[].Journal of Hepatology.2000
3Gines P,Jimenez W.Aquaretic agent: a new potential treatment of dilutional hyponatremia in cirrhosis[].Journal of Hepatology.1996
4Gines P,Jimenez W.Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis[].Journal of Hepatology.1996
5Bosch-Marce M,Jimenez W,Angeli P,et al.Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention[].Gastroenterology.1995
6Bosch-Marce M,Poo JL,Jimenez W,et al.Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention[].Journal of Pharmacology and Experimental Therapeutics.1999
7Borroni G,Maggi A,Sangiovanni A,et al.Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients[].Digestive and Liver Disease.2000
8Serradeil-Le-Gal C.Nonpeptide antagonists for vasopressin receptors.Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist[].Advances in Experimental Medicine and Biology.1998
9Yamamura Y,Ogawa H,Yamashita H,et al.Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist[].British Journal of Pharmacology.1992
10Gulberg V,Moller S,Henriksen JH,et al.Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure[].Gut.2000
